Understanding MOTS-c
MOTS-c is a mitochondrial-derived peptide discussed in metabolic and exercise-related research. Its biological role is being investigated, but animal findings and observational human studies do not establish clinical benefits from injected MOTS-c.
Compound Type
Mitochondrial-derived peptide
Origin
Encoded by mitochondrial DNA
Main Research Areas
Metabolic regulation, exercise-related pathways, and cellular energy signaling
Mechanism
Studied for its involvement in metabolic signaling and cellular responses to energy stress.
Evidence Level
Primarily animal research and observational human biology; human injection outcomes remain uncertain.
Important Distinction
Research involving MOTS-c analogs does not validate the safety or effectiveness of native MOTS-c.
Important Research Notice
MOTS-c is an experimental research peptide. Community-reported injection schedules should not be interpreted as clinically validated protocols.
Community-Reported Use Patterns
The following schedules are community-reported examples from the reference document. They are not validated human treatment protocols or recommendations.
SC example
Per administration
Frequency
Daily total
Reported cycle
Twice-Weekly Pattern
5 mg per administration
Twice weekly
Not applicable – weekly schedule
4 weeks, followed by a 4-week off-period
Three-Times-Weekly Pattern
5 mg per administration
Three times weekly
Not applicable – weekly schedule
4–6 weeks, followed by a 4–6-week off-period
Higher-Amount Pattern
10 mg per administration
Two to three times weekly
Not applicable – weekly schedule
6–8 weeks, followed by a 6–8-week off-period
Per administration
5 mg per administration
Daily total
Not applicable – weekly schedule
Reported cycle
4 weeks, followed by a 4-week off-period
Three-Times-Weekly Pattern
Per administration
5 mg per administration
Frequency
Three times weekly
Daily total
Not applicable – weekly schedule
Reported cycle
4–6 weeks, followed by a 4–6-week off-period
Per administration
10 mg per administration
Frequency
Two to three times weekly
Daily total
Not applicable – weekly schedule
Reported cycle
6–8 weeks, followed by a 6–8-week off-period
These schedules describe reported community practices only. They do not establish safe or effective human dosing, and native MOTS-c human outcomes remain uncertain.
No Validated Human Injection Protocol
Animal studies and community-reported schedules cannot establish a safe human dose, treatment duration, or expected metabolic benefit.
Safety Concerns and Research Limitations
Human safety information for MOTS-c remains limited. Reported concerns include injection-site reactions, fatigue, and headache. Long-term risks and interactions have not been adequately established.
Storage and Product Handling
Storage Conditions
The source describes cold and protected-from-light handling, but exact conditions depend on the specific product.
Mixed Product Stability
Reported storage windows vary. No universal mixed-vial lifetime is established.
Product Quality
Research-product identity, purity, and formulation should be independently verified.
Handling Considerations
Supplier storage claims should not be treated as validated stability data for every MOTS-c formulation.
Example Concentration Calculation
This mathematical example illustrates concentration and U-100 volume relationships. It is not a mixing, preparation, or administration instruction.
Amount (mg)
Final volume (mL)
Concentration (mg/mL)
Per 1 U (mcg)
Per 10 U (mcg)
10 mg
1 mL
10 mg/mL
100 mcg
1,000 mcg
Not specified
Not specified
Not specified
Not specified
Not specified
Concentration (mg/mL)
10 mg/mL
Amount (mg)
Not specified
Final volume (mL)
Not specified
Concentration (mg/mL)
Not specified
Per 1 U (mcg)
Not specified
Per 10 U (mcg)
Not specified
U refers to a U-100 volume marking, where 1 U = 0.01 mL. This is a calculation example only, not an instruction for mixing or administration.
Research Findings and Evidence Limitations
MOTS-c research focuses on mitochondrial signaling, metabolic regulation, and exercise-related pathways. Animal findings and observational human biology do not establish clinical benefits from peptide injections.
Metabolic Research
Experimental research investigates MOTS-c involvement in metabolic regulation and cellular energy responses. These findings do not prove weight-loss or metabolic treatment benefits in humans.
Exercise-Related Pathways
Animal studies have explored exercise-related and metabolic effects. These results cannot independently establish improved human exercise performance.
Human Evidence Limitations
Observational human biology and research involving MOTS-c analogs do not validate native MOTS-c injection schedules or establish long-term human safety.
Regulatory and Research Disclaimer
Experimental Research Compound
MOTS-c is an experimental mitochondrial-derived peptide. The source discusses regulatory and compounding-category changes separately from FDA approval. Such changes do not establish FDA approval, clinical effectiveness, or a validated human dosing protocol.
This page is provided for educational and research-information purposes only. It is not medical advice, a prescription, or a recommendation to use MOTS-c. Consult a qualified healthcare professional before considering any experimental compound.
